Cardiff Oncology, Inc.
CRDF
$4.00
$0.051.27%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -8.48% | 1.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.48% | 1.23% | |||
| Cost of Revenue | 0.75% | 1.55% | |||
| Gross Profit | -0.91% | -1.55% | |||
| SG&A Expenses | -3.68% | -2.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.34% | 0.46% | |||
| Operating Income | 0.23% | -0.45% | |||
| Income Before Tax | 0.57% | -0.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.57% | -0.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.57% | -0.65% | |||
| EBIT | 0.23% | -0.45% | |||
| EBITDA | 0.19% | -0.48% | |||
| EPS Basic | 14.07% | 3.73% | |||
| Normalized Basic EPS | 14.04% | 3.71% | |||
| EPS Diluted | 14.07% | 3.73% | |||
| Normalized Diluted EPS | 14.04% | 3.71% | |||
| Average Basic Shares Outstanding | 15.69% | 4.55% | |||
| Average Diluted Shares Outstanding | 15.69% | 4.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
